Thrombomodulin analogues for the treatment of ischemic stroke

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 6, 2011, Pages 1171-1173

  Andreou, A P ^a   Crawley, J T B ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 5A; BLOOD CLOTTING FACTOR 8A; ENDOTHELIAL PROTEIN C RECEPTOR; HEPARIN; PROTEINASE ACTIVATED RECEPTOR 1; SOLULIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLOOD CLOTTING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL PROTECTION; COMPETITIVE INHIBITION; DIABETIC NEPHROPATHY; DOWN REGULATION; DRUG EFFICACY; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; MIDDLE CEREBRAL ARTERY; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; NOTE; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REGULATORY MECHANISM; REPERFUSION; STOICHIOMETRY; STROKE;

ANIMALS; MALE; RECEPTORS, THROMBIN; RECOMBINANT PROTEINS; STROKE; THROMBOSIS;

EID: 79958023744     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04292.x     Document Type: Note

References (19)

1. WHO. The Global Burden of Disease. Geneva: World Health Organization, 2004 Update; WHO Library Cataloguing-in-Publication Data. ISBN 978 92 4 156371 0.
2. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333: 1581-7.
3. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999; 282: 2019-26.
4. Su EJ, Geyer M, Wahl M, Mann K, Ginsburg D, Brohmann H, Petersen K, Lawrence D. The thrombomodulin analogue solulin promotes reperfusion and reduces infract volume in a thrombotic model of stroke. J Thromb Haemost 2011; 9: 1174-82.
5. Mosnier LO, Meijers JC, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85: 5-11.
6. Griffin JH, Fernandez JA, Gale AJ, Mosnier LO. Activated protein C. J Thromb Haemost 2007; 5 (Suppl. 1): 73-80.
7. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-72.
8. Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb 1992; 12: 135-45.
9. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
10. Isermann B, Vinnikov IA, Madhusudhan T, Herzog S, Kashif M, Blautzik J, Corat MA, Zeier M, Blessing E, Oh J, Gerlitz B, Berg DT, Grinnell BW, Chavakis T, Esmon CT, Weiler H, Bierhaus A, Nawroth PP. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007; 13: 1349-58.
11. Griffin JH, Fernandez JA, Liu D, Cheng T, Guo H, Zlokovic BV. Activated protein C and ischemic stroke. Crit Care Med 2004; 32: S247-53.
12. Mizutani A, Okajima K, Uchiba M, Noguchi T. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 2000; 95: 3781-7.
13. van Sluis GL, Niers TM, Esmon CT, Tigchelaar W, Richel DJ, Buller HR, van Noorden CJ, Spek CA. Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement. Blood 2009; 114: 1968-73.
14. Zhong Z, Ilieva H, Hallagan L, Bell R, Singh I, Paquette N, Thiyagarajan M, Deane R, Fernandez JA, Lane S, Zlokovic AB, Liu T, Griffin JH, Chow N, Castellino FJ, Stojanovic K, Cleveland DW, Zlokovic BV. Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest 2009; 119: 3437-49.
15. van Iersel T, Stroissnig H, Giesen P, Wemer J, Wilhelm-Ogunbiyi K. Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue. Thromb Haemost 2011; 105: 302-12.
16. Sandercock P, Counsell C, Kamal AK. Anticoagulants for acute ischemic stroke. Stroke 2009; 40: e483-4.
17. Wang Y, Thiyagarajan M, Chow N, Singh I, Guo H, Davis TP, Zlokovic BV. Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke 2009; 40: 1864-9.
18. Esmon CT, Glass JD. The APCs of neuroprotection. J Clin Invest 2009; 119: 3205-7.
19. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.